AU2001220765A1 - Mixed buffer system for stabilizing polypeptide formulations - Google Patents

Mixed buffer system for stabilizing polypeptide formulations

Info

Publication number
AU2001220765A1
AU2001220765A1 AU2001220765A AU2076501A AU2001220765A1 AU 2001220765 A1 AU2001220765 A1 AU 2001220765A1 AU 2001220765 A AU2001220765 A AU 2001220765A AU 2076501 A AU2076501 A AU 2076501A AU 2001220765 A1 AU2001220765 A1 AU 2001220765A1
Authority
AU
Australia
Prior art keywords
buffer system
mixed buffer
polypeptide formulations
stabilizing polypeptide
stabilizing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001220765A
Inventor
Poonam S. Gulati
William Peter Van Antwerp
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medtronic Minimed Inc
Original Assignee
Minimed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minimed Inc filed Critical Minimed Inc
Publication of AU2001220765A1 publication Critical patent/AU2001220765A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/28Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
AU2001220765A 2000-01-24 2000-12-08 Mixed buffer system for stabilizing polypeptide formulations Abandoned AU2001220765A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17789700P 2000-01-24 2000-01-24
US60177897 2000-01-24
PCT/US2000/033358 WO2001052937A1 (en) 2000-01-24 2000-12-08 Mixed buffer system for stabilizing polypeptide formulations

Publications (1)

Publication Number Publication Date
AU2001220765A1 true AU2001220765A1 (en) 2001-07-31

Family

ID=22650368

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001220765A Abandoned AU2001220765A1 (en) 2000-01-24 2000-12-08 Mixed buffer system for stabilizing polypeptide formulations

Country Status (3)

Country Link
US (1) US6734162B2 (en)
AU (1) AU2001220765A1 (en)
WO (1) WO2001052937A1 (en)

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8688188B2 (en) 1998-04-30 2014-04-01 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US6175752B1 (en) 1998-04-30 2001-01-16 Therasense, Inc. Analyte monitoring device and methods of use
US8346337B2 (en) 1998-04-30 2013-01-01 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8974386B2 (en) 1998-04-30 2015-03-10 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US6949816B2 (en) 2003-04-21 2005-09-27 Motorola, Inc. Semiconductor component having first surface area for electrically coupling to a semiconductor chip and second surface area for electrically coupling to a substrate, and method of manufacturing same
US9066695B2 (en) 1998-04-30 2015-06-30 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8480580B2 (en) 1998-04-30 2013-07-09 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8465425B2 (en) 1998-04-30 2013-06-18 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US6560471B1 (en) 2001-01-02 2003-05-06 Therasense, Inc. Analyte monitoring device and methods of use
DE10114178A1 (en) * 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinc-free and low-zinc insulin preparations with improved stability
US7041468B2 (en) 2001-04-02 2006-05-09 Therasense, Inc. Blood glucose tracking apparatus and methods
US6737401B2 (en) 2001-06-28 2004-05-18 Metronic Minimed, Inc. Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom
PT1412384E (en) 2001-06-28 2008-03-28 Novo Nordisk As Stable formulation of modified glp-1
DE10227232A1 (en) * 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Sour insulin preparations with improved stability
US20090035260A1 (en) * 2002-07-29 2009-02-05 Therapicon Srl Enhanced nasal composition of active peptide
ITMI20021684A1 (en) * 2002-07-29 2004-01-29 Therapicon Srl PHARMACEUTICAL COMPOSITION OF NASAL PEPTIDE
EP1578262A4 (en) 2002-12-31 2007-12-05 Therasense Inc Continuous glucose monitoring system and methods of use
US8771183B2 (en) 2004-02-17 2014-07-08 Abbott Diabetes Care Inc. Method and system for providing data communication in continuous glucose monitoring and management system
AU2004232858B2 (en) 2003-04-23 2009-07-09 Mannkind Corporation Hydraulically actuated pump for long duration medicament administration
JP4936884B2 (en) 2003-06-03 2012-05-23 ノボ・ノルデイスク・エー/エス Stabilized pharmaceutical peptide composition
JP2007524592A (en) 2003-06-03 2007-08-30 ノボ・ノルデイスク・エー/エス Stabilized pharmaceutical peptide composition
US8066639B2 (en) 2003-06-10 2011-11-29 Abbott Diabetes Care Inc. Glucose measuring device for use in personal area network
RU2421238C2 (en) 2003-11-20 2011-06-20 Ново Нордиск А/С Peptide composition containing propylene glycol optimal for manufacturing and application in injection devices
ITMI20040235A1 (en) * 2004-02-13 2004-05-13 Therapicon Srl PHARMACEUTICAL PREPARATION FOR THE ORAL CABLE
WO2006014425A1 (en) 2004-07-02 2006-02-09 Biovalve Technologies, Inc. Methods and devices for delivering glp-1 and uses thereof
RU2393168C2 (en) 2004-07-19 2010-06-27 Биокон Лимитед Insulin-oligomer conjugates, preparations and use thereof
US8710181B2 (en) 2004-08-31 2014-04-29 Novo Nordisk A/S Use of tris(hydroxymethyl) aminomethane for the stabilization of peptides, polypeptides and proteins
CA2586771A1 (en) 2004-11-12 2006-05-18 Novo Nordisk A/S Stable formulations of insulinotropic peptides
CN101106979A (en) * 2005-01-21 2008-01-16 阿尔扎公司 Therapeutic peptide formulations for coating microneedles with improved stability containing at least one counterion
US8112240B2 (en) 2005-04-29 2012-02-07 Abbott Diabetes Care Inc. Method and apparatus for providing leak detection in data monitoring and management systems
JP5235661B2 (en) * 2005-05-25 2013-07-10 ノボ・ノルデイスク・エー/エス Stabilized polypeptide preparation
US20090060861A1 (en) * 2005-05-25 2009-03-05 Novo Nordisk A/S Stabilized Polypeptide Formulations
WO2007037795A2 (en) 2005-08-05 2007-04-05 Amgen Inc. Stable aqueous protein or antibody pharmaceutical formulations and their preparation
US7766829B2 (en) 2005-11-04 2010-08-03 Abbott Diabetes Care Inc. Method and system for providing basal profile modification in analyte monitoring and management systems
US20070191271A1 (en) * 2006-02-10 2007-08-16 Dow Pharmaceutical Sciences Method for stabilizing polypeptides lacking methionine
EP2982399B1 (en) 2006-03-30 2017-12-06 Valeritas, Inc. Multi-cartridge fluid delivery device
US8226891B2 (en) 2006-03-31 2012-07-24 Abbott Diabetes Care Inc. Analyte monitoring devices and methods therefor
US7620438B2 (en) 2006-03-31 2009-11-17 Abbott Diabetes Care Inc. Method and system for powering an electronic device
US20080071158A1 (en) 2006-06-07 2008-03-20 Abbott Diabetes Care, Inc. Analyte monitoring system and method
GB0700523D0 (en) * 2007-01-11 2007-02-21 Insense Ltd The Stabilisation Of Proteins
US8732188B2 (en) 2007-02-18 2014-05-20 Abbott Diabetes Care Inc. Method and system for providing contextual based medication dosage determination
US8930203B2 (en) 2007-02-18 2015-01-06 Abbott Diabetes Care Inc. Multi-function analyte test device and methods therefor
US8123686B2 (en) 2007-03-01 2012-02-28 Abbott Diabetes Care Inc. Method and apparatus for providing rolling data in communication systems
US8456301B2 (en) 2007-05-08 2013-06-04 Abbott Diabetes Care Inc. Analyte monitoring system and methods
US8461985B2 (en) 2007-05-08 2013-06-11 Abbott Diabetes Care Inc. Analyte monitoring system and methods
US8665091B2 (en) 2007-05-08 2014-03-04 Abbott Diabetes Care Inc. Method and device for determining elapsed sensor life
US7928850B2 (en) 2007-05-08 2011-04-19 Abbott Diabetes Care Inc. Analyte monitoring system and methods
EP2203181B1 (en) 2007-10-16 2018-02-14 Biocon Limited An orally administerable solid pharmaceutical composition and a process thereof
AU2009212166A1 (en) 2008-02-07 2009-08-13 University Of Washington Circumferential aerosol device
CN102037008B (en) 2008-03-18 2016-08-31 诺沃-诺迪斯克有限公司 Protease stabilized, acylated insulin analog
TWI451876B (en) * 2008-06-13 2014-09-11 Lilly Co Eli Pegylated insulin lispro compounds
CN109010254A (en) 2008-08-15 2018-12-18 硬木药品公司 It is suitble to the stable solid pharmaceutical preparation of the guanylate cyclase-C receptor agonist polypeptide of oral administration
LT2349324T (en) 2008-10-17 2017-12-27 Sanofi-Aventis Deutschland Gmbh Combination of an insulin and a glp-1 agonist
US8103456B2 (en) 2009-01-29 2012-01-24 Abbott Diabetes Care Inc. Method and device for early signal attenuation detection using blood glucose measurements
US9226701B2 (en) 2009-04-28 2016-01-05 Abbott Diabetes Care Inc. Error detection in critical repeating data in a wireless sensor system
WO2010138856A1 (en) 2009-05-29 2010-12-02 Abbott Diabetes Care Inc. Medical device antenna systems having external antenna configurations
JP5669834B2 (en) * 2009-06-26 2015-02-18 ノボ・ノルデイスク・エー/エス Formulation containing insulin, nicotinamide and amino acid
US20110027229A1 (en) 2009-07-31 2011-02-03 Medtronic, Inc. Continuous subcutaneous administration of interferon-alpha to hepatitis c infected patients
WO2011017502A2 (en) 2009-08-06 2011-02-10 Ironwood Pharmaceuticals, Inc. Linaclotide-containing formulations for oral administration
WO2011026147A1 (en) 2009-08-31 2011-03-03 Abbott Diabetes Care Inc. Analyte signal processing device and methods
EP2473099A4 (en) 2009-08-31 2015-01-14 Abbott Diabetes Care Inc Analyte monitoring system and methods for managing power and noise
EP2482720A4 (en) 2009-09-29 2014-04-23 Abbott Diabetes Care Inc Method and apparatus for providing notification function in analyte monitoring systems
ES2855146T3 (en) 2009-11-13 2021-09-23 Sanofi Aventis Deutschland Pharmaceutical composition comprising a GLP-1 agonist, an insulin and methionine
TWI468171B (en) 2009-11-13 2015-01-11 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist and methionine
US20110152820A1 (en) * 2009-12-22 2011-06-23 Medtronic Minimed, Inc. Barrier coatings for fluids contacting medical devices
US20160243199A1 (en) * 2015-02-25 2016-08-25 Dance Biopharm, Inc. Liquid insulin formulations and methods relating thereto
MX340234B (en) 2010-02-17 2016-07-01 Ironwood Pharmaceuticals Inc Treatments for gastrointestinal disorders.
HUE046922T2 (en) 2010-08-11 2020-03-30 Ironwood Pharmaceuticals Inc Stable formulations of linaclotide
CN103179978A (en) 2010-08-30 2013-06-26 赛诺菲-安万特德国有限公司 Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
RU2728583C2 (en) 2011-03-03 2020-07-30 Импел Ньюрофарма Инк. Device for nasal drug delivery
WO2012154859A1 (en) 2011-05-09 2012-11-15 Impel Neuropharma Inc. Nozzles for nasal drug delivery
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
PL2776055T3 (en) 2011-08-17 2017-06-30 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
JP6367115B2 (en) 2011-08-29 2018-08-01 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Combination medicine used for blood glucose control in patients with type 2 diabetes
AR087744A1 (en) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OF A NEURODEGENERATIVE DISEASE
WO2013070794A2 (en) 2011-11-07 2013-05-16 Abbott Diabetes Care Inc. Analyte monitoring device and methods
WO2013158276A1 (en) * 2012-04-20 2013-10-24 Children's Hospital Medical Center Antibody binding microbial heparin binding motif to retard or prevent microbial biofilm formation on implanted medical devices
US9662445B2 (en) 2012-08-30 2017-05-30 Medtronic Minimed, Inc. Regulating entry into a closed-loop operating mode of an insulin infusion system
US9878096B2 (en) 2012-08-30 2018-01-30 Medtronic Minimed, Inc. Generation of target glucose values for a closed-loop operating mode of an insulin infusion system
US10496797B2 (en) 2012-08-30 2019-12-03 Medtronic Minimed, Inc. Blood glucose validation for a closed-loop operating mode of an insulin infusion system
US9364609B2 (en) 2012-08-30 2016-06-14 Medtronic Minimed, Inc. Insulin on board compensation for a closed-loop insulin infusion system
US9849239B2 (en) 2012-08-30 2017-12-26 Medtronic Minimed, Inc. Generation and application of an insulin limit for a closed-loop operating mode of an insulin infusion system
US9623179B2 (en) 2012-08-30 2017-04-18 Medtronic Minimed, Inc. Safeguarding techniques for a closed-loop insulin infusion system
US10130767B2 (en) 2012-08-30 2018-11-20 Medtronic Minimed, Inc. Sensor model supervisor for a closed-loop insulin infusion system
US9968306B2 (en) 2012-09-17 2018-05-15 Abbott Diabetes Care Inc. Methods and apparatuses for providing adverse condition notification with enhanced wireless communication range in analyte monitoring systems
KR102205512B1 (en) 2012-11-13 2021-01-20 아도시아 Quick-acting insulin formulation including a substituted anionic compound
WO2014096985A2 (en) 2012-12-19 2014-06-26 Wockhardt Limited A stable aqueous composition comprising human insulin or an analogue or derivative thereof
AU2013368990B2 (en) 2012-12-26 2017-05-18 Wockhardt Limited Pharmaceutical composition
US10537692B2 (en) 2013-04-28 2020-01-21 Impel Neuropharma, Inc. Medical unit dose container
CR20170314A (en) 2014-12-12 2017-10-20 Sanofi Aventis Deutschland FORMULATION OF GLARGINE / LIXISENATIDA INSULIN FIXED RELATIONSHIP
TWI748945B (en) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 Treatment type 2 diabetes mellitus patients
TW201705975A (en) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 Treatment of type 2 diabetes mellitus patients
EP3341059B1 (en) 2015-09-10 2022-03-02 Impel NeuroPharma Inc. In-line nasal delivery device
TWI700092B (en) 2016-12-16 2020-08-01 丹麥商諾佛.儂迪克股份有限公司 Insulin containing pharmaceutical compositions
KR20200044016A (en) 2017-08-24 2020-04-28 노보 노르디스크 에이/에스 GLP-1 composition and use
WO2019104205A1 (en) 2017-11-21 2019-05-31 Impel Neuropharma, Inc. Intranasal device with dip tube
WO2019104192A1 (en) 2017-11-21 2019-05-31 Impel Neuropharma, Inc. Intranasal device with inlet interface
US11278492B2 (en) 2018-01-05 2022-03-22 Impel Neuropharma, Inc. Intranasal delivery of olanzapine by precision olfactory device
JP7317020B2 (en) 2018-01-05 2023-07-28 インペル ファーマシューティカルズ インコーポレイテッド Intranasal delivery of dihydroergotamine by a precision olfactory device
EP3823607A4 (en) 2018-07-19 2022-04-06 Impel NeuroPharma Inc. Respiratory tract delivery of levodopa and dopa decarboxylase inhibitor for treatment of parkinson's disease
BR112021013244A8 (en) 2019-01-03 2022-10-18 Impel Neuropharma Inc NASAL DRUG DELIVERY DEVICE
WO2020236658A1 (en) 2019-05-17 2020-11-26 Impel Neuropharma, Inc. Single-use nasal delivery device
PE20221575A1 (en) 2020-02-18 2022-10-06 Novo Nordisk As PHARMACEUTICAL FORMULATIONS

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5767548A (en) * 1980-10-14 1982-04-24 Shionogi & Co Ltd Insulin analog and its preparation
US4839341A (en) * 1984-05-29 1989-06-13 Eli Lilly And Company Stabilized insulin formulations
GB9320782D0 (en) 1993-10-08 1993-12-01 Univ Leeds Innovations Ltd Stabilising of proteins on solution
US5474978A (en) 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5547929A (en) 1994-09-12 1996-08-20 Eli Lilly And Company Insulin analog formulations
EP0726075A1 (en) 1995-02-08 1996-08-14 Therapicon Srl Pharmaceutical non-inorganic saline solutions for endonasal administration
AR002976A1 (en) 1995-03-31 1998-05-27 Lilly Co Eli PARENTERAL PHARMACEUTICAL FORMULATIONS OF LONG-TERM EFFECT OF INSULIN; CRYSTALS OF SUCH ANALOGUES APPLICABLE IN SUCH FORMULATIONS AND PROCEDURE OF THE FORMULATIONS MENTIONED
PE79099A1 (en) 1997-06-13 1999-08-24 Lilly Co Eli STABLE INSULIN FORMULATIONS
CO4970787A1 (en) * 1997-12-23 2000-11-07 Lilly Co Eli INSOLUBLE COMPOSITIONS OF INSULIN AND INSULIN DERIVATIVES THAT CONTROL BLOOD GLUCOSE
JP2002500196A (en) 1998-01-09 2002-01-08 ノヴォ ノルディスク アクティーゼルスカブ Stabilized insulin composition
JP2002517241A (en) 1998-06-11 2002-06-18 アストラゼネカ アクチボラグ Human receptor tyrosine kinase

Also Published As

Publication number Publication date
US6734162B2 (en) 2004-05-11
WO2001052937A1 (en) 2001-07-26
US20010031726A1 (en) 2001-10-18

Similar Documents

Publication Publication Date Title
AU2001220765A1 (en) Mixed buffer system for stabilizing polypeptide formulations
AU2001236005A1 (en) Preparations stabilized over long time
AUPR022300A0 (en) Cement render system
AU2001294192A1 (en) Solid preparations
AU2001281096A1 (en) Bone anchoring system
AU2001282617A1 (en) Compositions for external preparations
AU2001282607A1 (en) Solution preparations stabilized over long time
EP1032211A3 (en) Moving picture transcoding system
AU2001242020A1 (en) Imaging system
AU6386801A (en) System for the release of active ingredients
AU2002232803A1 (en) Expression system for recombinant proteins
AU2002236588A1 (en) System for direct sequence spreading
AU2001275409A1 (en) Methods and compositions for controlled polypeptide synthesis
AU2002232707A1 (en) Transmembrane proteins
AU2001286996A1 (en) Stabilized fgf formulations containing reducing agents
AU2001280674A1 (en) Mini-adenoviral vector system for vaccination
AU3455000A (en) Composition for decomposing protein
AU2001281464A1 (en) Recombinant proteins containing repeating units
AU2001272427A1 (en) Solid preparations
AU2002239747A1 (en) Cystoskeleton-associated proteins
AU2002224379A1 (en) Clasp-2 transmembrane proteins
AU2001253548A1 (en) Video messaging system
AU2232399A (en) Recombinant ctb-based vaccines
AU1137300A (en) Cement formulation
AU2002224056A1 (en) Novel polypeptide